The presence of EGFR mutations in paired CTC-derived gDNA analyzed for the first time in a group of NSCLC patients under osimertinib and the discrepancies found between CTC fractions and tumor or cfDNA genotyping, confirmed previous evidence about spatial and temporal tumor heterogeneity and clonal evolution. This evidence concerns the gene EGFR and neoplasm.